The final sales contract replaces all prior agreements and understandings, both orally and in writing between buyer and seller. A CCA is sometimes referred to as a “share purchase agreement” or a “definitive merger agreement.” On a pro forma basis and based on the number of Dkers common shares that will be issued in connection with the merger, Akers` current shareholders will own approximately 20% of the combined business on a fully diluted basis and current MyMD shareholders will own approximately 80% of the combined business on a fully diluted basis (excluding the effect of the option warrants issued under the private placement described below). The merger agreement also provides, in certain circumstances, for additional cash and share payments to MyMD shareholders. The merger is expected to be completed in the first half of 2021, subject to the agreement of Akers` shareholders at a special meeting of shareholders and other normal closing conditions. A typical guarantee is that the seller complies with state rules, the Worker`s Compensation Act, intellectual property laws and has the legal authority to sign the agreement, etc. Duncan Peyton, Chief Executive Officer of 4D Pharma, said: “A Nasdaq listing allows 4D to benefit from the increased interest of US healthcare investors in recent years. access more special capital and increase our global profile and commitment. Nasdaq is a very positive environment for innovative and growing biotech companies. The merger with LOAC accelerates and puts at risk our entry into the U.S., while providing immediate access to additional funds to support our pipeline. The increase in the presence of a U.S.
listing will also support ongoing partnership discussions across our pipeline. Here are a few things not included in the agreement: The combined company is led by Chris Chapman, M.D., who becomes President and Chief Medical Officer of MyMD, and Adam Kaplin, M.D., the Chief Scientific Officer of MyMD, and its headquarters in Baltimore, Maryland. Dr. Chapman is the founder and CEO of Chapman Pharmaceutical Consulting Inc. and will bring extensive experience in collaborating with biotech companies in the design of clinical trial protocols, conducting clinical trials, and advising on regulatory and medical matters. . . .